Piston Bio is a clinical-stage biotechnology company developing therapies to overcome immune resistance in cancer.

Our lead program, PST-101, is a best-in-class adenosine A2A receptor antagonist targeting a clinically validated immune checkpoint. We are advancing a randomized Phase 2 study in 2L+ non-small cell lung cancer, with progression-free survival as the primary endpoint.

PST-101 is an oral, combination-ready therapy designed to integrate with standard of care and improve clinical outcomes.

Piston Bio is focused on translating validated biology into meaningful survival benefit for patients with cancer.

Piston Bio

Org chart

Teams

Offices